Hilmar Bading

Hilmar Bading was born in Berlin on 3 November 1958. He studied medicine from 1978 to 1984 at Heidelberg University (MD in 1984) and carried out his MD Thesis at the Max Planck Institute for Medical Research, Heidelberg, with Wilhelm Hasselbach on the calcium transport ATPase in skeletal muscle. He received postdoctoral training in the laboratory of Karin Mölling at the Max Planck Institute for Molecular Genetics, Berlin, Germany (1985–1989) and in the laboratory of Michael E. Greenberg at Harvard Medical School, Boston, US (1989–1993). From 1993 to 2001 he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge, UK. Since 2001 he has been professor of neurobiology and director of the Neurobiology Institute and the Interdisciplinary Center for Neurosciences (IZN) at Heidelberg University.[1][2]

He is co-founder of FundaMental Pharma GmbH, Heidelberg.[3]

Hilmar Bading is noted for his work on neuronal calcium signaling and gene regulation in the nervous system.[4] He identified calcium as the principal second messenger in the coupling of neuronal activity to gene expression and characterized the processes that mediate the dialogue between the synapse and the nucleus.[5][6] His work highlighted the spatial aspects of calcium signals[7][8] and in particular the importance of nuclear calcium in governing activity-dependent gene expression and adaptations in the nervous system that include memory formation and acquired neuroprotection.[9][10][11][12] The discovery of toxic signaling by extrasynaptic NMDA receptors that antagonizes gene regulation by synaptic activity and causes neuronal dysfunction and cell death[13][14] contributed to the understanding of neurodegenerative disorders including Huntington's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).[13][14][15][16][17][18]

2001: Wolfgang-Paul Prize of the Alexander von Humboldt Foundation[19]

2016: Innovation Prize of the German BioRegions[20]